{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:49:36Z","timestamp":1790711376482,"version":"4.1.0"},"reference-count":146,"publisher":"Bentham Science Publishers Ltd.","issue":"15","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2019,9,4]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Nowadays, heterocyclic compounds act as a scaffold and are the backbone of medicinal\nchemistry. Among all of the heterocyclic scaffolds, 1,4-Dihydropyridine (1,4-DHP) is one of the most\nimportant heterocyclic rings that possess prominent therapeutic effects in a very versatile manner and\nplays an important role in synthetic, medicinal, and bioorganic chemistry. The main aim of the study is\nto review and encompass relevant studies related to 1,4-DHP and excellent therapeutic benefits of its\nderivatives. An extensive review of Pubmed-Medline, Embase and Lancet\u2019s published articles was\ndone to find all relevant studies on the activity of 1,4-DHP and its derivatives. 1,4-DHP is a potent\nVoltage-Gated Calcium Channel (VGCC) antagonist derivative which acts as an anti-hypertensive, anti-\nanginal, anti-tumor, anti-inflammatory, anti-tubercular, anti-cancer, anti-hyperplasia, anti-mutagenic,\nanti-dyslipidemic, and anti-ulcer agent. From the inferences of the study, it can be concluded that the\nbasic nucleus, 1,4-DHP which is a voltage-gated calcium ion channel blocker, acts as a base for its derivatives\nthat possess different important therapeutic effects. There is a need of further research of this\nbasic nucleus as it is a multifunctional moiety, on which addition of different groups can yield a better\ndrug for its other activities such as anti-convulsant, anti-oxidant, anti-mutagenic, and anti-microbial.\nThis review would be significant for further researches in the development of several kinds of drugs by\nrepresenting successful matrix for the medicinal agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557519666190425184749","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T11:17:23Z","timestamp":1556191043000},"page":"1219-1254","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["1,4-Dihydropyridine: A Dependable Heterocyclic Ring with the Promising and the Most Anticipable Therapeutic Effects"],"prefix":"10.2174","volume":"19","author":[{"given":"Abhinav Prasoon","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Pranveer Singh Institute of Technology, Kanpur, 209305, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Bajpai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pranveer Singh Institute of Technology, Kanpur, 209305, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awani Kumar","family":"Rai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pranveer Singh Institute of Technology, Kanpur, 209305, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1039\/C6RA24823C","volume":"7","author":"Sharma V.K.","year":"2017","unstructured":"Sharma V.K.; Singh S.K.; Synthesis, utility and medicinal importance of 1,2","journal-title":"RSC Adv"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/1389557513666131119204126","volume":"14","author":"Khedkar S.A.","year":"2014","unstructured":"Khedkar S.A.; Auti P.B.; 1,4-Dihydropyridines: A class of pharmacologically important molecules. Mini Rev Med Chem 2014,14(3),282-290","journal-title":"Mini Rev Med Chem"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"S001","DOI":"10.1016\/j.jscs.2012.07.011","volume":"20","author":"Mansoor S.S.","year":"2016","unstructured":"Mansoor S.S.; Aswin K.; Logaiya K.; Sudhan S.P.N.; Bismuth nitrate as an efficient recyclable catalyst for the one-pot multi component synthesis of 1, 4-dihydropyridine derivatives through unsymmetrical hantzsch reaction. J Saudi Chem Soc 2016,20(1),S001-S008","journal-title":"J Saudi Chem Soc"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0223-5234(00)01189-2","volume":"35","author":"Kappe C.O.","year":"2000","unstructured":"Kappe C.O.; Biologically active dihydropyrimidones of the Biginelli-type -a literature survey. Eur J Med Chem 2000,35(12),1043-1052","journal-title":"Eur J Med Chem"},{"key":"ref=5","first-page":"75","volume":"3","author":"Swarnalatha G.","year":"2011","unstructured":"Swarnalatha G.; Prasanthi G.; Sirisha N.; Chetty C.M.; 1,4-Dihydropyridines: A multtifunctional molecule- A review. Int J Chemtech Res 2011,3,75-89","journal-title":"Int J Chemtech Res"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/cr00048a004","volume":"82","author":"Stout D.M.","year":"1982","unstructured":"Stout D.M.; Meyers A.I.; Recent advances in the chemistry of dihydropyridines. Chem Rev 1982,82(2),223-243","journal-title":"Chem Rev"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/cr60275a001","volume":"72","author":"Eisner U.","year":"1972","unstructured":"Eisner U.; Kuthan J.; The chemistry of dihydropyridines. Chem Rev 1972,72(1),1-42","journal-title":"Chem Rev"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/i300006a012","volume":"21","author":"Kuthan J.","year":"1882","unstructured":"Kuthan J.; Kurfurst A.; Development in dihydropyridine chemistry. Ind Eng Chem Prod Res Dev 1882,21(2),191-261","journal-title":"Ind Eng Chem Prod Res Dev"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0014-5793(88)81026-3","volume":"241","author":"Hofmann H.J.","year":"1988","unstructured":"Hofmann H.J.; Cimiraglia R.; Conformation of 1, 4- dihydropyridine- planar or boat-like? FBBS Lett 1988,241(1,2),38-40","journal-title":"FBBS Lett"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm00152a023","volume":"29","author":"Fossheim R.","year":"1986","unstructured":"Fossheim R.; Crystal structure of the dihydropyridine ca antagonist felodipine. Dihydropyridine binding prerequisites assessed from crystallographic data. J Med Chem 1986,29(2),305-307","journal-title":"J Med Chem"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-2999(85)90631-4","volume":"114","author":"Franckowiak G.","year":"1985","unstructured":"Franckowiak G.; Bechem M.; Schramm M.; Thomas G.; The optical isomers of the 1,4-dihydropyridine bay k 8644 show opposite Effects on ca channels. Eur J Pharmacol 1985,114(2),223-226","journal-title":"Eur J Pharmacol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1021\/jm00167a021","volume":"33","author":"Goldmann S.","year":"1990","unstructured":"Goldmann S.; Born L.; Kazda S.; Pittel B.; Schramm M.; Synthesis, pharmacological effects, and conformation of 4,4-disubstituted 1,4-dihydropyridines. J Med Chem 1990,33(5),1413-1418","journal-title":"J Med Chem"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/anie.199115591","volume":"30","author":"Goldmann G.","year":"1991","unstructured":"Goldmann G.; Stoltefuss J.; 1,4-Dihydropyridines: Effects of chirality and conformation on the calcium antagonist and calcium agonist activities. Angew Chem Int Ed Engl 1991,30(12),1559-1578","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/jm00001a017","volume":"38","author":"Rovnyak G.C.","year":"1995","unstructured":"Rovnyak G.C.; Kimball S.D.; Beyer B.; Cucinotta S.G.; DiMarco J.D.; Gougoutas J.; Hedberg A.; Malley M.; McCarthy J.P.; Zhang R.; Morelande S.; Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J Med Chem 1995,38(1),119-129","journal-title":"J Med Chem"},{"key":"ref=15","first-page":"160","volume":"2","author":"Aronow W.S.","year":"2012","unstructured":"Aronow W.S.; Treatment of systemic hypertension. Am J Cardiovasc Dis 2012,2(3),160-170","journal-title":"Am J Cardiovasc Dis"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.supflu.2015.08.021","volume":"107","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Song Z.; Dong Y.; Wang Y.; Li X.; Long H.; Xu K.; Deng C.; Meng M.; Yin Y.; Xi R.; Enantiomeric separation of 1, 4-dihydropyridines by liquid-phase microextraction with supercritical fluid chromatography. J Supercrit Fluids 2016,107,129-136","journal-title":"J Supercrit Fluids"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.tetlet.2014.12.118","volume":"56","author":"Yu F.","year":"2015","unstructured":"Yu F.; Zhou B.; Xu H.; Chang K.; Shen Y.; An atom-economic green approach: Oxidative synthesis of functionalized 1,4-dihydropyridines from N,N-dimethylenaminones and amines. Tetrahedron Lett 2015,56(6),837-841","journal-title":"Tetrahedron Lett"},{"key":"ref=18","first-page":"12","volume":"4","author":"Cataldi M.","year":"2012","unstructured":"Cataldi M.; Bruno F.; 1,4-Dihydropyridines: The multiple personalities of a blockbuster drug family. Transl Med UniSa 2012,4(2),12-26","journal-title":"Transl Med UniSa"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/203518","volume":"2014","author":"Shaldam M.A.","year":"2014","unstructured":"Shaldam M.A.; Elhamamsy M.H.; Esmat E.A.; El-moselhy T.F.; 1,4-Dihydropyridine calcium channel blockers: Homology modeling of the receptor and assessment of structure-activity relationship. ISRN Med Chem 2014,2014,1-14","journal-title":"ISRN Med Chem"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.05.032","volume":"155","author":"Schaller D.","year":"2018","unstructured":"Schaller D.; Gunduz M.G.; Zhang F.X.; Zamponi G.W.; Wolber G.; Binding mechanism investigations guiding the synthesis of a novel condensed 1,4- dihydropyridine derivatives with L-\/T-type calcium channel blocking activity. Eur J Med Chem 2018,155,1-12","journal-title":"Eur J Med Chem"},{"key":"ref=21","first-page":"67","volume":"14","author":"Wang A.L.","year":"2017","unstructured":"Wang A.L.; Iadecola C.; Wang G.; New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol 2017,14(1),67-72","journal-title":"J Geriatr Cardiol"},{"key":"ref=22","first-page":"R25","volume":"307","author":"Fleckenstein A.","year":"1969","unstructured":"Fleckenstein A.; Tritthart H.; Flackenstein B.; Herbst A.; Grun G.; A new group of competitive divalent Ca-antagonists (iproveratril, D 600, prenylamine) with potent inhibitory effects on electromechanical coupling in mammalian myocardium. Pflugers Arch [Article in German].1969,307(2),R25","journal-title":"Pflugers Arch"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/erc.12.155","volume":"11","author":"Coca A.","year":"2013","unstructured":"Coca A.; Mazon P.; Redon J.; Divison J.A.; Mart\u00ednez J.; Calvo C.; Galceran M.; Bareios V.; Coll A.R.; Role of dihydropyridine calcium channel blockers in the management of hypertension. Expert Rev Cardiovasc Ther 2013,11(1),91-105","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/hr.2010.259","volume":"34","author":"Wang J.","year":"2011","unstructured":"Wang J.; Kario K.; Lau T.; Wei Y.Q.; Park C.G.; Kim C.H.; Huang J.; Zhang W.; Li W.; Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian pacific heart association. Hypertens Res 2011,34(4),423-430","journal-title":"Hypertens Res"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/14779072.3.2.207","volume":"3","author":"Liau C.","year":"2005","unstructured":"Liau C.; Barnidipine: A new calcium channel blocker for hypertension treatment. Exp Revi Cardio Ther 2005,3(2),207-213","journal-title":"Exp Revi Cardio Ther"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/080370598438999","volume":"7","author":"Van Zwieten P.A.","year":"1998","unstructured":"Van Zwieten P.A.; The pharmacological properties of lipophilic calcium antagonists. Blood Press Suppl 1998,7(2),5-9","journal-title":"Blood Press Suppl"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ihj.2013.11.001","volume":"65","author":"Chandra K.S.","year":"2013","unstructured":"Chandra K.S.; Ramesh G.; The fourth-generation calcium channel blocker: Cilnidipine. Ind Heart J 2013,65(6),691-695","journal-title":"Ind Heart J"},{"key":"ref=28","first-page":"00148","volume":"5","author":"Salazar T.","year":"2017","unstructured":"Salazar T.; Gonzalez A.; Bandyopadhaya D.; Dihydropyridines as calcium channel blockers: An overview. J Anal Pharm Res 2017,5(4),00148","journal-title":"J Anal Pharm Res"},{"key":"ref=29","first-page":"1","volume":"43","author":"Ozer E.K.","year":"2017","unstructured":"Ozer E.K.; MiyaseGunduz, M.G.; El-Khouly. A.; Sara, Y.; Simsek, R.; Iskit, A.B.; Safak, C. Synthesis of fused 1,4-dihydropyridines as potential calcium channel blockers. Turk J Biochem 2017,43(6),1-9","journal-title":"Turk J Biochem"},{"key":"ref=30","first-page":"451","volume":"14","author":"Mohajeri S.A.","year":"2011","unstructured":"Mohajeri S.A.; Hosseinzadeh H.; Salami S.; Motamedshariaty V.; Hadizadeh F.; Synthesis of novel 4-[1-(4-fluorobenzyl) -5-imidazolyl] dihydropyridines and studying their effects on rat blood pressure. Iran J Basic Med Sci 2011,14(5),451-457","journal-title":"Iran J Basic Med Sci"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00044-010-9477-0","volume":"20","author":"Zhou K.","year":"2011","unstructured":"Zhou K.; Zhao Y.; Wang X.; Cao Y.; Fu Q.; Zhang S.; Synthesis and antihypertensive activity evaluation in spontaneously hypertensive rats of nitrendipine analogs. Med Chem Res 2011,20(8),1325-1330","journal-title":"Med Chem Res"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11094-010-0396-7","volume":"44","author":"Balaev A.N.","year":"2010","unstructured":"Balaev A.N.; Eleev A.F.; Eremin O.G.; Fedorov V.E.; Synthesis and antihypertensive activity of 1,4-dihydropyridines containing 3-dialkylamino-2,2-dimethyl propyl fragments. Pharm Chem J 2010,44(2),56-57","journal-title":"Pharm Chem J"},{"key":"ref=33","first-page":"193","volume":"8","author":"Nekooeian A.A.","year":"2009","unstructured":"Nekooeian A.A.; Khalili A.; Javidnia K.; Mehdipour A.R.; Miri R.; Antihypertensive effects of some new nitroxyalkyl 1, 4-dihydropyridine derivatives in the rat model of two-kidney, one-clip hypertension. Iran J Pharm Res 2009,8(3),193-199","journal-title":"Iran J Pharm Res"},{"key":"ref=34","first-page":"85","volume":"2","author":"Hadizadeh F.","year":"2007","unstructured":"Hadizadeh F.; Fatehi-Hassanabad Z.; Fatehi-Hassanabad M.; Beheshtizadeh A.; Nabati F.; Synthesis and antihypertensive activity of novel 4-[1-(4-X-benzyl)-5-imidazolyl] dihydropyridines in the rat. Res Pharm Sci 2007,2(2),85-90","journal-title":"Res Pharm Sci"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0968-0896(01)00318-2","volume":"10","author":"Liang J.","year":"2002","unstructured":"Liang J.; Yeh J.; Wang C.; Liou S.; Tsai C.; Chen I.; The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display \u221d-\/\u03b2-adrenoceptor antagonist and long-acting antihypertensive activities. Bioorg Med Chem 2002,10,719-730","journal-title":"Bioorg Med Chem"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1248\/cpb.41.1049","volume":"41","author":"Ogawa T.","year":"1993","unstructured":"Ogawa T.; Nakazato A.; Tsuchida K.; Hatayama K.; Synthesis and antihypertensive activity of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5- position. Chem Pharm Bull 1993,41(6),1049-1054","journal-title":"Chem Pharm Bull"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/anie.198107621","volume":"20","author":"Bossert B.F.","year":"1981","unstructured":"Bossert B.F.; Meyer H.; Wehinger E.; 4-Aryldihydropyridines, a new class of highly active calcium antagonists. Angew Chem Int Ed Engl 1981,20(9),762-769","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ejmech.2017.10.073","volume":"143","author":"Matos H.L.S.","year":"2018","unstructured":"Matos H.L.S.; Masson F.T.; Simeoni L.A.; Homem-de-mello, M. biological activity of dihydropyrimidinone (DHPM) derivatives: A systematic review. Eur J Med Chem 2018,143,1779-1789","journal-title":"Eur J Med Chem"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2165\/00003495-198734050-00005","volume":"34","author":"Freedman D.D.","year":"1987","unstructured":"Freedman D.D.; Waters D.D.; Dihydropyridine calcium antagonists greater vascular selectivity and some unique applications. Drugs 1987,34(5),578-598","journal-title":"Drugs"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jscs.2012.08.003","volume":"20","author":"Datar P.A.","year":"2016","unstructured":"Datar P.A.; Auti P.B.; Design and synthesis of novel 4-substituted 1, 4-dihydropyridine derivatives as hypotensive agents. J Saudi Chem Soc 2016,20(5),510-516","journal-title":"J Saudi Chem Soc"},{"key":"ref=41","first-page":"413","volume":"15","author":"Razzaghi-asl N.","year":"2016","unstructured":"Razzaghi-asl N.; Miri R.; Firuzi O.; Assessment of the cytotoxic effect of a series of 1, 4-dihydropyridine derivatives against human cancer cells. Iran J Pharm Res 2016,15(3),413-420","journal-title":"Iran J Pharm Res"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejmech.2010.10.024","volume":"46","author":"Al-Said M.S.","year":"2011","unstructured":"Al-Said M.S.; Bashandy M.S.; Al-qasoumi S.I.; Ghorab M.M.; Anti-breast cancer activity of some novel 1, 2-dihydropyridine, thiophene and thiazole derivatives. Eur J Med Chem 2011,46(1),137-141","journal-title":"Eur J Med Chem"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejphar.2017.12.009","volume":"819","author":"Goto R.N.","year":"2018","unstructured":"Goto R.N.; Sobral L.M.; Sousa L.O.; Garcia C.B.; Lopes N.P.; Marin-Prida J.; Ochoa-Rodriguez E.; Verdecia-Reyes Y.; Pardo-Andreu G.L.; Curti C.; Leopoldino A.M.; Anti-cancer activity of a new dihydropyridine derivative, VdiE-2N, in head and neck squamous cell carcinoma. Eur J Pharmacol 2018,819,198-206","journal-title":"Eur J Pharmacol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/00397911.2017.1422521","volume":"48","author":"Kumar R.","year":"2018","unstructured":"Kumar R.; Gahlyan P.; Verma A.; Jain R.; Das S.; Konwar R.; Prasad A.K.; Design and synthesis of fluorescent symmetric bis-triazolylated-1,4-dihydropyridines as potent anti-breast cancer agents. Synth Commun 2018,48(7),778-785","journal-title":"Synth Commun"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2174\/1871520616666161206143251","volume":"17","author":"Viradiya D.","year":"2017","unstructured":"Viradiya D.; Mirza S.; Shaikh F.; Kakadiya R.; Rathod A.; Jain N.; Rawal R.; Shah A.; Design and synthesis of 1,4-dihydropyridine derivatives as anti-cancer agent. Anticancer Agents Med Chem 2017,17(7),1003-1013","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10565-007-9026-x","volume":"24","author":"Bazargan L.","year":"2008","unstructured":"Bazargan L.; Fouladdel S.; Shafiee A.; Amini M.; Ghaffari S.M.; Azizi E.; Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro. Cell Biol Toxicol 2008,24(2),165-174","journal-title":"Cell Biol Toxicol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s12039-015-0983-y","volume":"127","author":"Dhinakaran I.","year":"2015","unstructured":"Dhinakaran I.; Padmini V.; Bhuvanesh N.; One-pot synthesis of N-aryl 1,4-dihydropyridine derivatives and their biological activities. J Chem Sci 2015,127(12),2201-2209","journal-title":"J Chem Sci"},{"key":"ref=48","first-page":"183","volume":"5","author":"Aziz H.M.","year":"2013","unstructured":"Aziz H.M.; Gomha S.M.; Synthesis and in vitro anti-breast cancer activity of some novel 1,4-dihydropyridine derivatives. Int J Pharm Pharm Sci 2013,5(3),183-189","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ardp.200900243","volume":"343","author":"Sirisha K.","year":"2010","unstructured":"Sirisha K.; Achaiah G.; Reddy V.M.; Facile synthesis and antibacterial, antitubercular and anticancer activities of novel 1, 4-dihydropyridines. Arch Pharm Chem Life Sci 2010,343(6),342-352","journal-title":"Arch Pharm Chem Life Sci"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1211\/jpp.60.11.0009","volume":"60","author":"Foroughinia F.","year":"2008","unstructured":"Foroughinia F.; Javidnia K.; Amirghofran Z.; Mehdipour A.; Miri R.; Design and synthesis of new symmetrical derivatives of dihydropyridine containing a pyridyl group on the 3, 5-positions and evaluation of their cytotoxic and multidrug resistance reversal activity. J Pharm Pharmacol 2008,60(11),1481-1489","journal-title":"J Pharm Pharmacol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.02.001","volume":"563","author":"Saponara S.","year":"2007","unstructured":"Saponara S.; Ferrara A.; Gorelli B.; Shah A.; Kawase M.; Motohashi N.; Molnar J.; Sgaragli G.; Fusi F.; 3,5-dibenzoyl-4-(3-phenoxyphenyl)-1, 4-dihydro-2,6-dimethylpyridine (DP7): A new multidrug resistance inhibitor devoid of effects on langendorff-perfused rat heart. Eur J Pharmacol 2007,563(1-3),160-163","journal-title":"Eur J Pharmacol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0968-0896(01)00363-7","volume":"10","author":"Kawase M.","year":"2002","unstructured":"Kawase M.; Shah A.; Gaveriya H.; Motohashi N.; Sakagami H.; Varga A.; Molna J.; 3,5-dibenzoyl-1,4-dihydropyridines: Synthesis and MDR reversal in tumor cells. Bioorg Med Chem 2002,10(4),1051-1055","journal-title":"Bioorg Med Chem"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.phytochem.2005.06.008","volume":"66","author":"Marquez B.","year":"2005","unstructured":"Marquez B.; Neuville L.; Moreau N.J.; Genet J.; dos Santos A.F.; Cano-de-Andrade M.C.; Sant, Ana A.E.G. Multidrug resistance reversal agent from jatropha elliptica. Phytochemistry 2005,66(15),1804-1811","journal-title":"Phytochemistry"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ddmec.2007.11.003","volume":"4","author":"Arentz M.","year":"2007","unstructured":"Arentz M.; Hawn T.R.; Tuberculosis infection: Insight from immunogenomics. Drug Discov Today Dis Mech 2007,4(4),231-236","journal-title":"Drug Discov Today Dis Mech"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.bmc.2007.01.030","volume":"15","author":"Janin Y.L.","year":"2007","unstructured":"Janin Y.L.; Antituberculosis drugs: Ten years of research. Bioorg Med Chem 2007,15(7),2479-2513","journal-title":"Bioorg Med Chem"},{"key":"ref=56","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040825","volume":"23","author":"Lentz F.","year":"2018","unstructured":"Lentz F.; Reiling N.; Martins A.; Molnar J.; Hilgeroth A.; Discovery of novel enhancers of isoniazid toxicity in mycobacterium tuberculosis. Molecules 2018,23(4)","journal-title":"Molecules"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1573409913666170426154045","volume":"14","author":"Rasouli Y.","year":"2018","unstructured":"Rasouli Y.; Davood A.; Hybrid docking-QSAR studies of 1, 4-dihydropyridine-3, 5-dicarboxamides as potential antitubercular agents. Curr Comput Aided Drug Des 2018,14(1),35-53","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1016\/j.bmcl.2016.11.010","volume":"26","author":"Hilgeroth A.","year":"2016","unstructured":"Hilgeroth A.; Reiling N.; Hemmer M.; Lentz F.; Discovery of novel N-phenyl 1,4 dihydropyridines with a dual mode of antimycobacterial activity. Bioorg Med Chem Lett 2016,26(24),5896-5898","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=59","first-page":"791","volume":"15","author":"Iman M.","year":"2016","unstructured":"Iman M.; Davood, A.; Lotfinia, M.; Dehqani, G.; Sardari, S.; Azerang, P.; Amini, M. design, synthesis and anti-tubercular activity of novel 1, 4-dihydropyrine-3,5 dicarboxamide containing 4(5)-chloro-2-ethyl- 5(4)-imidazolyl moiety. Iran J Pharmaceut Res 2016,15(4),791-799","journal-title":"Iran J Pharmaceut Res"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1016\/j.bmcl.2011.07.068","volume":"21","author":"Trivedi A.R.","year":"2011","unstructured":"Trivedi A.R.; Dodiya D.K.; Dholariya B.H.; Kataria V.B.; Bhuva V.R.; Shah V.H.; Synthesis and biological evaluation of some novel N-aryl-1,4-dihydropyridines as potential antitubercular agents. Bioorg Med Chem Lett 2011,21(18),5181-5183","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1016\/j.ejmech.2009.03.027","volume":"44","author":"Fassihi A.","year":"2009","unstructured":"Fassihi A.; Azadpour Z.; Delbari N.; Saghaie L.; Memarian H.R.; Sabet R.; Alborzi A.; Miri R.; Pourabbas R.; Mardanehe J.; Mousavi P.; Moeinifardf B.; Sadeghi-Ali A.H.; Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides. Eur J Med Chem 2009,44(8),3253-3258","journal-title":"Eur J Med Chem"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bmc.2008.12.070","volume":"17","author":"Khoshneviszadeh M.","year":"2009","unstructured":"Khoshneviszadeh M.; Edraki N.; Javidnia K.; Alborzi A.; Pourabbas B.; Mardanehc J.; Miri R.; Synthesis and biological evaluation of some new 1, 4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg Med Chem 2009,17(4),1579-1586","journal-title":"Bioorg Med Chem"},{"key":"ref=63","first-page":"323","volume":"19","author":"Shafii B.","year":"2008","unstructured":"Shafii B.; Amini M.; Akbarzadeh T.; Shafiee A.; Synthesis and antitubercular activity of N3, N5-diaryl-4- (5-aryl isoxazole-3-yl)-1,4-dihydropyridine- 3,5-dicarboxamide. J Sci IR Iran 2008,19(4),323-328","journal-title":"J Sci IR Iran"},{"key":"ref=64","first-page":"199","volume":"65","author":"Nasrollahi S.M.H.","year":"2018","unstructured":"Nasrollahi S.M.H.; Ghasemzadeh M.A.; Zolfaghari M.R.; Synthesis and antibacterial evaluation of somenew 1,4 dihydropyridines in the presence of FeO@silica sulfonic acid nanocomposite as catalyst. Acta. Chem Slov 2018,65(1),199-207","journal-title":"Chem Slov"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.sjbs.2018.03.001","volume":"25","author":"Ahamed A.","year":"2018","unstructured":"Ahamed A.; Arif I.A.; Mateen M.; Kumar R.S.; Idhayadhulla A.; Antimicrobial, anticoagulant, and cytotoxic evaluation of multidrug resistance of new 1,4-dihydropyridine derivatives. Saudi J Biol Sci 2018,25(6),1227-1235","journal-title":"Saudi J Biol Sci"},{"key":"ref=66","first-page":"142","volume":"7","author":"Narsinghani T.","year":"2017","unstructured":"Narsinghani T.; Soni L.K.; Chourey S.; Synthesis and antimicrobial activity of 1,4-dihydropyridine derivative. J Drug Deliv Ther 2017,7(7),142-145","journal-title":"J Drug Deliv Ther"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jscs.2017.07.004","volume":"22","author":"Moradi L.","year":"2018","unstructured":"Moradi L.; Mahinpour R.; Zahraei Z.; Pahlevanzadeh N.; New synthetic method for the Synthesis of 1,4-dihydropyridine using aminated multiwalled carbon nanotubes as high efficient catalyst and investigation of their antimicrobial properties. J Saudi Chem Soc 2018,22(7),876-885","journal-title":"J Saudi Chem Soc"},{"key":"ref=68","first-page":"77","volume":"54","author":"Elumalai K.","year":"2016","unstructured":"Elumalai K.; Elumalai M.; Eluri K.; Facile synthesis, spectral characterization, antimicrobial and in vitro cytotoxicity of novel N, N-diisonicotinyl-2,6-dimethyl-4-phenyl-1, 4-dihydropyridine-3,5-dicarbohydrazide derivatives. Bull Fac Pharm 2016,54(1),77-86","journal-title":"Bull Fac Pharm"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/865128","volume":"2013","author":"Mehta P.","year":"2013","unstructured":"Mehta P.; Verma P.; Antimicrobial activity of some derivatives of 1,4-dihydropyridines. J Chem 2013,2013,1-4","journal-title":"J Chem"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2298\/JSC091127003K","volume":"76","author":"Kumar R.S.","year":"2011","unstructured":"Kumar R.S.; Idhayadhulla A.; Nasser A.J.A.; Selvin J.; Synthesis and antimicrobial activity of a new series of 1,4-dihydropyridine derivatives. J Serb Chem Soc 2011,76(1),1-11","journal-title":"J Serb Chem Soc"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ejmech.2009.10.036","volume":"45","author":"Kumar A.","year":"2010","unstructured":"Kumar A.; Maurya R.A.; Sharma S.; Kumar M.; Bhatia G.; Synthesis and biological evaluation of N-aryl-1,4-dihydropyridines as novel antidyslipidemic and antioxidant agents. Eur J Med Chem 2010,45(2),501-509","journal-title":"Eur J Med Chem"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/1892412","volume":"2016","author":"Velena A.","year":"2016","unstructured":"Velena A.; Zarkovic N.; Troselj K.G.; Bisenieks E.; Krauze A.; Poikans J.; Duburs G.; 1,4-Dihydropyridine derivatives: Dihydronicotinamide analogues - model compounds targeting oxidative stress. Oxid Med Cell Longev 2016,2016,1-35","journal-title":"Oxid Med Cell Longev"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2018.11.009","volume":"84","author":"Cabreraa D.D.C.","year":"2019","unstructured":"Cabreraa D.D.C.; Santa-Helenab E.; Leala H.P.; Mouraa R.R.D.; Neryb L.E.M.; Goncalvesb C.A.N.; Russowskyc D.; D\u2019Ocaa M.A.M.; Synthesis and antioxidant activity of new lipophilic dihydropyridines. Bioorg Chem 2019,84,1-16","journal-title":"Bioorg Chem"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s40242-016-6047-0","volume":"32","author":"Yang G.","year":"2016","unstructured":"Yang G.; Bowei W.; Shang G.; Ruhui Z.; Chunying Y.; Zheng S.; Zhihui L.; Design and synthesis of 1,4-dihydropyridine and cinnamic acid esters and their antioxidant properties. Chem Res Chin Univ 2016,32(4),594-599","journal-title":"Chem Res Chin Univ"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.crci.2013.07.003","volume":"17","author":"Rucins M.","year":"2014","unstructured":"Rucins M.; Kaldre D.; Pajuste K.; Fernandes M.A.S.; Vicente J.A.F.; Klimaviciusa L.; Jaschenko E.; Kanepe-Lapsa I.; Shestakova I.; Plotniece M.; Gosteva M.; Sobolev A.; Jansone B.; Muceniece R.; Klusa V.; Plotniece A.; Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and\/or N-propargyl substituted 1, 4-dihydropyridine derivatives. Comptes Rendus Chem 2014,17,69-80","journal-title":"Comptes Rendus Chem"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1016\/j.ejmech.2011.09.026","volume":"46","author":"Vijesh A.M.","year":"2011","unstructured":"Vijesh A.M.; Isloor A.M.; Peethambar S.K.; Shivananda K.N.; Arulmoli T.; Isloor N.A.; Hantzsch reaction: Synthesis and characterization of some new 1, 4-dihydropyridine derivatives as potent antimicrobial and antioxidant agents. Eur J Med Chem 2011,46(11),5591-5597","journal-title":"Eur J Med Chem"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.17221\/6581-CJFS","volume":"19","author":"Tirzitis G.","year":"2001","unstructured":"Tirzitis G.; Tirzite D.; Hyvonen Z.; Antioxidant Activity of 2,6-Dimethyl-3,5-dialkoxycarbonyl -1,4-dihydropyridines in metal-ion catalyzed lipid peroxidation. Czech J Food Sci 2001,19(3),81-84","journal-title":"Czech J Food Sci"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bmc.2017.02.015","volume":"26","author":"Teleb M.","year":"2017","unstructured":"Teleb M.; Zhang F.; Huang J.; Gadotti V.M.; Farghaly A.M.; Aboulwafa O.M.; Zamponi G.W.; Fahmy H.; Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain. Bioorg Med Chem 2017,26(6),1926-1938","journal-title":"Bioorg Med Chem"},{"key":"ref=79","first-page":"738","volume":"4","author":"Nangare A.K.","year":"2015","unstructured":"Nangare A.K.; Kakad S.B.; Chavan A.N.; Bole S.S.; Synthesis and signification of 1, 4-dihydropyridines analogs in different pharmaceutical drug. World J Pharm Res 2015,4(12),738-749","journal-title":"World J Pharm Res"},{"key":"ref=80","first-page":"13","volume":"2","author":"Mishra B.","year":"2007","unstructured":"Mishra B.; Mishra R.; Synthesis of some new 1,4-dihydropyridine derivatives for anti-inflammatory activity. Pharmacist 2007,2,13-16","journal-title":"Pharmacist"},{"key":"ref=81","first-page":"434","volume":"7","author":"Indumathi S.","year":"2015","unstructured":"Indumathi S.; Karthikeyan R.; Nasser A.J.A.; Idhayadhulla A.; Kumar R.S.; Anticonvulsant, analgesic and anti-inflammatory activities of some novel pyrrole and 1,4-dihydropyridine derivatives. J Chem Pharm Res 2015,7(2),434-440","journal-title":"J Chem Pharm Res"},{"key":"ref=82","first-page":"246","volume":"2","author":"Pattan S.R.","year":"2010","unstructured":"Pattan S.R.; Dighe N.S.; Musmade D.S.; Tambe S.K.; Kale S.H.; Gaware V.M.; Chavan P.A.; Synthesis and evaluation of some new substituted 1,4-dihydro pyridine derivatives and their anticonvulsant activity. J Chem Pharm Res 2010,2(1),246-252","journal-title":"J Chem Pharm Res"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00044-008-9112-5","volume":"18","author":"Samzadeh-Kermani A.","year":"2009","unstructured":"Samzadeh-Kermani A.; Shafaroodi H.; Miri R.; Mirkhani H.; Vosooghi M.; Shafie A.; Lipo philic 2-(4-chlorophenyl)-4-thiazolyl-1,4-dihydropyridines: Synthesis, calcium channel antagonist activity, and protection against pentylenetetrazole-induced seizure. Med Chem Res 2009,18(2),112-126","journal-title":"Med Chem Res"},{"key":"ref=84","first-page":"81","volume":"12","author":"Shafiee A.","year":"2004","unstructured":"Shafiee A.; Rastkari N.; Sharifzadeh M.; Anticonvulsant activities of new 1,4-dihydropyridine derivatives containing 4-nitroimidazolyl substituents. DARU-J. Facul. Pharm 2004,12(2),81-86","journal-title":"Pharm"},{"key":"ref=85","first-page":"725","volume":"48","author":"Subudhia B.B.","year":"2009","unstructured":"Subudhia B.B.; Pandab P.K.; Bhatta D.; Synthesis and antiulcer activity study of 1, 4- dihydropyridines and their Mannich bases with sulfanilamide. Ind J Chem 2009,48,725-728","journal-title":"Ind J Chem"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejmech.2010.12.006","volume":"46","author":"Kumar R.S.","year":"2011","unstructured":"Kumar R.S.; Idhayadhulla A.; Nasser A.J.A.; Selvin J.; Synthesis and anticoagulant activity of a new series of 1,4-dihydropyridine derivatives. Eur J Med Chem 2011,46,804-810","journal-title":"Eur J Med Chem"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1021\/jm200199r","volume":"54","author":"Budriesi R.","year":"2011","unstructured":"Budriesi R.; Ioan P.; Leoni A.; Pedemonte N.; Locatelli A.; Micucci M.; Chiarini A.; Galietta L.J.V.; Cystic Fibrosis: A new target for 4-imidazo[2,1-b]thiazole-1, 4-dihydropyridines. J Med Chem 2011,54,3885-3894","journal-title":"J Med Chem"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"7894","DOI":"10.1016\/j.bmc.2009.10.028","volume":"17","author":"Cateni F.","year":"2009","unstructured":"Cateni F.; Zacchigna M.; Pedemonte N.; Galietta L.J.V.; Mazzei M.T.; Fossa P.; Giampieri M.; Mazzei M.; Synthesis of 4-thiophen-20-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel. Bioorg Med Chem 2009,17,7894-7903","journal-title":"Bioorg Med Chem"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.ejmech.2010.02.018","volume":"45","author":"Pandey V.P.","year":"2010","unstructured":"Pandey V.P.; Bisht S.S.; Mishra M.M.; Kumar A.A.; Siddiqi M.I.; Verma A.; Mittal M.; Sane S.A.; Gupta S.; Tripathi R.P.; Synthesis and molecular docking studies of 1-phenyl-4-glycosyl-dihydropyridines as potent antileishmanial agents. Eur J Med Chem 2010,45,2381-2385","journal-title":"Eur J Med Chem"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"7759","DOI":"10.1016\/j.bmc.2008.07.005","volume":"16","author":"Leon R.","year":"2008","unstructured":"Leon R.; Rios C.L.; Marco-Contelles J.; Huertas O.; Barril X.; Luque F.J.; Lopez M.G.; Garcia A.G.; Villarroya M.; New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection propertie. Bioorg Med Chem 2008,16,7759-7769","journal-title":"Bioorg Med Chem"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1021\/jm801292b","volume":"52","author":"Contelles J.M.","year":"2009","unstructured":"Contelles J.M.; Leon R.; Rios C.L.; Samadi A.L.; Bartolini M.; Andrisano V.; Huertas O.; Barril X.; Luque F.J.; Guez-Franco M.R.; Lopez B.; Lopez A.G.; Garcia A.G.; Carreiras M.C.; Villarroya M.; Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of alzheimer\u2019s disease. J Med Chem 2009,52,2724-2732","journal-title":"J Med Chem"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/antiox7090123","volume":"7","author":"Milkovic L.","year":"2018","unstructured":"Milkovic L.; Vukovic T.; Zarkovic N.; Tatzber F.; Bisenieks E.; Kalme, Z.; Bruvere, I.; Ogle, Z.; Poikans, J.; Velena, A.; Duburs, G. Antioxidative 1,4-dihydropyridine derivativesmodulate oxidative stress and growth of human osteoblast-like cells in vitro. Antioxidants 2018,7(9),123","journal-title":"Antioxidants"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3466.1990.tb00427.x","volume":"8","author":"Burges R.A.","year":"1990","unstructured":"Burges R.A.; Dodd M.G.; Amlodipine. Cardiovasc Drug Rev 1990,8(1),25-44","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.1996.tb00310.x","volume":"14","author":"Ohashi K.","year":"1996","unstructured":"Ohashi K.; Ebihara A.; Aranidipine (MPC- 1304), A new dihydropyridine calcium antagonist: A review of its antihypertensive action. Cardiovasc Drug Rev 1996,14(1),1-16","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2165\/00003495-200363230-00004","volume":"63","author":"Wellington K.","year":"2003","unstructured":"Wellington K.; Scott L.J.; Azelnidipine. Drugs 2003,63(23),2613-2621","journal-title":"Drugs"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003495-200161070-00007","volume":"61","author":"Malhotra H.S.","year":"2001","unstructured":"Malhotra H.S.; Plosker G.L.; Barnidipine. Drugs 2001,61(7),989-996","journal-title":"Drugs"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1254\/jphs.DTJ05001X","volume":"261","author":"Yao K.","year":"2006","unstructured":"Yao K.; Nagashima K.; Miki H.; New drugs and recent techniques pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel. J Pharmacol Sci 2006,261,243-261","journal-title":"J Pharmacol Sci"},{"key":"ref=98","first-page":"22","volume":"2","author":"Buchiya F.V.","year":"2014","unstructured":"Buchiya F.V.; Jain V.; Raj H.; A review\u03b1 : analytical methods for determination of cilnidipine in biological fluid and pharmaceutical dosage forms. Pharmatutor 2014,2(11),22-29","journal-title":"Pharmatutor"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-014-0313-6","volume":"74","author":"Keating G.M.","year":"2014","unstructured":"Keating G.M.; Clevidipine: A review of its use for managing blood pressure in perioperative and intensive care settings. Drugs 2014,74,1947-1960","journal-title":"Drugs"},{"key":"ref=100","first-page":"14","volume":"24","author":"Kastron V.V.","year":"1991","unstructured":"Kastron V.V.; Vitolin R.O.; Dubur G.Y.; Synthesis and pharmacological activity of 1,4-dihydropyridine. Translated from Khimiko-farmatsevticheskii Zhurnal 1991,24(6),14-21","journal-title":"Translated from Khimiko-farmatsevticheskii Zhurnal"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0047-6374(94)90085-X","volume":"75","author":"Vega J.A.","year":"1994","unstructured":"Vega J.A.; Sabbatini M.; Del M.E.; Amenta F.; Effect of treatment with the dihydropyridine-type calcium antagonist darodipine (PY 108-068) on the expression of neurofilament protein immunoreactivity in the cerebellar cortex of aged rats. Mech Ageing Dev 1994,75,169-177","journal-title":"Mech Ageing Dev"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0047-6374(94)01513-L","volume":"78","author":"Amenta F.","year":"1995","unstructured":"Amenta F.; Ferrantea F.; Mancini M.; Sabbatinia M.; Vegab A.; Zaccheoc D.; Effect of long term treatment with the dihydropyridine-type calcium channel blocker darodipine (PY 108-068) on the cerebral capillary network in aged rats. Mech Ageing Dev 1995,78,27-37","journal-title":"Mech Ageing Dev"},{"key":"ref=103","first-page":"123","volume":"12","author":"Masuda Y.","year":"1994","unstructured":"Masuda Y.; Tanaka S.; Efonidipine Hydrochloride: A new calcium antagonist. cardiovasc. Drug Rev 1994,12(2),123-135","journal-title":"Drug Rev"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/BF00878092","volume":"9","author":"Kuhn A.","year":"1995","unstructured":"Kuhn A.; Carlsson J.; Miketic S.; Tebbe U.; Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina. Cardiovasc Drugs Ther 1995,9,595-600","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0223-5234(92)90006-M","volume":"27","author":"Mannhold R.","year":"1992","unstructured":"Mannhold R.; Jablonkaz B.; Voigtl W.; Schgnafinger K.; Calcium- and calmodulin-antagonism of elnadipine derivatives: Comparative SAR. Eur J Med Chem 1992,27,229-235","journal-title":"Eur J Med Chem"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"2A-45S","DOI":"10.1016\/0002-9343(92)90294-L","volume":"93","author":"Prisant M.","year":"1992","unstructured":"Prisant M.; Bottini B.; Dipiro J.T.; Novel drug-delivery systems for hypertension. The Am J Med 1992,93,2A-45S-2A-55S","journal-title":"The Am J Med"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00005344-198405000-00004","volume":"6","author":"Leonetti G.","year":"1984","unstructured":"Leonetti G.; Gradnik R.; Terzoli L.; Fruscio M.; Rupoli L.; Zanchetti A.; Felodipine a new vasodilating drug: Blood pressure, cardiac, renal and humoral effects in hypertensive patients. J Cardiovasc Pharmacol 1984,6,392-398","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0021-9150(88)90292-4","volume":"69","author":"Kritchevsky D.","year":"1988","unstructured":"Kritchevsky D.; Tepper S.A.; Klurfeld D.M.; Flordipine, a calcium channel blocker, which does not influence lipidemia or atherosclerosis in cholesterol-fed rabbits. Atheroscler 1988,69,89-92","journal-title":"Atheroscler"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1021\/jm00015a005","volume":"38","author":"Alajarin R.","year":"1995","unstructured":"Alajarin R.; Vaquero J.J.; Alvarez-builla J.; Pastor M.; Sunkel C.; Casa-juana M.F.; Priego J.; Statkow P.R.; Sanz-Aparicio J.; Fonsecall I.; Synthesis, structure, and pharmacological evaluation of the stereoisomers of furnidipine. J Med Chem 1995,38(15),2830-2841","journal-title":"J Med Chem"},{"key":"ref=110","first-page":"91","volume":"549","author":"Krzemi T.F.","year":"2006","unstructured":"Krzemi T.F.; Grzyb J.; Porc M.P.; Chatterjee S.S.; Anti-arrhythmic and cardio-protective effects of furnidipine in a rat model: A dose response study. Cardiovasc Drug Rev 2006,549(1-3),91-97","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1527-3466.1996.tb00227.x","volume":"14","author":"Yamada S.","year":"1996","unstructured":"Yamada S.; Kimura R.; Pharmacodynamics and pharmacokinetics of iganidipine. Cardiovasc Drug Rev 1996,14(3),213-230","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2165\/00003495-199549040-00009","volume":"49","author":"Brogden R.N.","year":"1995","unstructured":"Brogden R.N.; Sorkin E.M.; Mild to moderate hypertension isradipine. Drugs 1995,49(4),618-649","journal-title":"Drugs"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.2165\/00003495-200363210-00008","volume":"63","author":"Mccormack P.L.","year":"2003","unstructured":"Mccormack P.L.; Wagstaff A.J.; Meredith P.A.; Infirmary W.; Lacidipine a review of its use in the management of hypertension. Drugs 2003,63(21),2327-2356","journal-title":"Drugs"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2165\/00003495-199448020-00010","volume":"48","author":"Lee C.R.","year":"1994","unstructured":"Lee C.R.; Bryson H.M.; Lacidipine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs 1994,48(2),274-296","journal-title":"Drugs"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2165\/00003495-200060050-00009","volume":"60","author":"Mcclellan K.J.","year":"2000","unstructured":"Mcclellan K.J.; Jarvis B.; Lercanidipine review of its use in hypertension. Drugs 2000,60(5),1123-1140","journal-title":"Drugs"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2165\/00003495-200363220-00013","volume":"63","author":"Bang L.M.","year":"2003","unstructured":"Bang L.M.; Chapman T.M.; Goa K.L.; Lercanidipine a review of its efficacy in the management of hypertension. Drugs 2003,63(22),2449-2472","journal-title":"Drugs"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/8681792","volume":"2018","author":"Dalal J.","year":"2018","unstructured":"Dalal J.; Mohan J.C.; Iyengar S.S.; Hiremath J.; Sathyamurthy, I. Bansal, S. Kahali D Dasbiswas A. S-amlodipine: An isomer with difference - time to shift from racemic amlodipine. Int J Hypertens 2018,2018(1999),1-14","journal-title":"Int J Hypertens"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2165\/00003495-200161120-00010","volume":"61","author":"Cheer S.M.","year":"2001","unstructured":"Cheer S.M.; Clellan K.M.; Manidipine: A review of its use in hypertension. Drugs 2001,61(12),1777-1799","journal-title":"Drugs"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2165\/00003495-200565002-00003","volume":"65","author":"Roca-cusachs A.","year":"2005","unstructured":"Roca-cusachs A.; Triposkiadis F.; Antihypertensive effect of manidipine. Drugs 2005,65,2-, 11-19","journal-title":"Drugs"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2165\/00003495-200464170-00011","volume":"64","author":"Mckeage K.","year":"2004","unstructured":"Mckeage K.; Scott L.J.; Manidipine a review of its use in the management of hypertension. Drugs 2004,64(17),1923-1940","journal-title":"Drugs"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2165\/00003495-198733040-00002","volume":"345","author":"Sorkin E.M.","year":"1987","unstructured":"Sorkin E.M.; Clissold S.P.; Nicardipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders nicardipine. Drugs 1987,345,296-345","journal-title":"Drugs"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00002512-199303020-00007","volume":"3","author":"Frampton J.E.","year":"1993","unstructured":"Frampton J.E.; Faulds D.; Nicardipine a review of its pharmacology and therapeutic efficacy in older patients. Drugs Aging 1993,3(2),165-187","journal-title":"Drugs Aging"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s004670050400","volume":"12","author":"Michael J.","year":"1998","unstructured":"Michael J.; Groshong T.; Tobias J.D.; Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 1998,12,40-42","journal-title":"Pediatr Nephrol"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/bmj.287.6387.257","volume":"287","author":"Dollery C.T.","year":"1983","unstructured":"Dollery C.T.; Murphy M.B.; Scriven A.J.I.; Role of nifedipine in treatment of hypertension. Br Med J 1983,287,257-259","journal-title":"Br Med J"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00148474","volume":"3","author":"Macgregor G.A.","year":"1989","unstructured":"Macgregor G.A.; Nifedipine and hypertension\u03b1 : Roles of vasodilation and sodium balance. Cardiovasc Drugs Ther 1989,3,295-301","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF00542507","volume":"25","author":"Brennan F.","year":"1983","unstructured":"Brennan F.; Flanagan M.; Blake S.; Cannon P.; Nifedipine in the treatment of hypertension. Eur J Clin Pharmacol 1983,25,7-9","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00374478","volume":"420","author":"Romanin C.","year":"1992","unstructured":"Romanin C.; Seyd K.; Glossmann H.; Schindler H.; The dihydropyridine niguldipine inhibits T-type Ca currents in atrial myocytes. Eur J Physiol 1992,420(3-4),410-412","journal-title":"Eur J Physiol"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FBP.0000000000000204","volume":"27","author":"Kreiner G.","year":"2016","unstructured":"Kreiner G.; Roman A.; Zelek-molik A.; Kowalska M.; Nalepa I.; Lack of \u03b1 1A -adrenergic receptor-mediated antidepressant-like effects of S-(+)- niguldipine and B8805-88033 in the forced swim test. Behav Pharmacol 2016,27(4),397-401","journal-title":"Behav Pharmacol"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10384-010-0862-5","volume":"54","author":"Ishida S.","year":"2010","unstructured":"Ishida S.; Koto T.; Nagai N.; Oike Y.; Calcium channel blocker nilvadipine, but not diltiazem, inhibits ocular infl ammation in endotoxin-induced uveitis. Jpn J Ophthalmol 2010,54(6),594-601","journal-title":"Jpn J Ophthalmol"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2165\/00002512-199506020-00007","volume":"6","author":"Brogden R.N.","year":"1995","unstructured":"Brogden R.N.; Mctavish D.; Nilvadipine a review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina. Drugs Aging 1995,6(2),150-171","journal-title":"Drugs Aging"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/gps.1851","volume":"22","author":"Hanyu H.","year":"2007","unstructured":"Hanyu H.; Hirao K.; Shimizu S.; Sato T.; Kiuchi A.; Iwamoto T.; Nilvadipine prevents cognitive decline of patients with mild cognitive impairment. Int J Geriatr Psychiat 2007,22(12),1264-1266","journal-title":"Int J Geriatr Psychiat"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-198937050-00004","volume":"37","author":"Langley M.S.","year":"1989","unstructured":"Langley M.S.; Sorkin E.M.; Nimodipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 1989,37(5),669-699","journal-title":"Drugs"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/00002512-199506030-00006","volume":"6","author":"Muck W.","year":"1995","unstructured":"Muck W.; Ahr G.; Kuhlmann J.; Nimodipine potential for drug-drug interactions in the elderly. Drugs Aging 1995,6(3),229-242","journal-title":"Drugs Aging"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00003495-198733020-00003","volume":"155","author":"Goa K.L.","year":"1987","unstructured":"Goa K.L.; Sorkin E.M.; Nitrendipine a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987,155,123-155","journal-title":"Drugs"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(89)90229-5","volume":"86","author":"Byyny R.L.","year":"1989","unstructured":"Byyny R.L.; Loverde M.; Mitchell W.; Denver P.D.; Treatment of hypertension in the elderly with a new calcium channel blocking drug, nitrendipine. Am J Med 1989,86(1),49-55","journal-title":"Am J Med"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF02209081","volume":"1","author":"Knorr A.","year":"1987","unstructured":"Knorr A.; The pharmacology of nisoldipine. Cardiovasc Drugs Ther 1987,1(4),393-402","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/BF00051614","volume":"10","author":"Fodor J.G.","year":"1997","unstructured":"Fodor J.G.; Nisoldipine C.C.; Efficacy and tolerability in hypertension and ischemic heart disease. Cardiovasc Drugs Ther 1997,10(3),873-879","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-2999(98)00543-3","volume":"357","author":"Galan L.","year":"1998","unstructured":"Galan L.; Talavera K.; Vassort G.; Alvarez J.L.; Characteristics of Ca 2 channel blockade by oxodipine and elgodipine in rat cardiomyocytes. Eur J Pharmacol 1998,357,93-105","journal-title":"Eur J Pharmacol"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF00809549","volume":"114","author":"Karpova M.N.","year":"1992","unstructured":"Karpova M.N.; Antonikov I.M.; Pankov O.Y.; Glebov R.N.; Organic calcium antagonists verapamil and riodipine prevent elevation of free calcium level in rat brain synaptosomes during metrazol kindling. Bull Exp Biol Med 1992,114(9),252-254","journal-title":"Bull Exp Biol Med"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/BF00842284","volume":"110","author":"Tirzite A.J.","year":"1991","unstructured":"Tirzite A.J.; Tirzite G.D.; Dubur G.J.; Effect of nifedipine and riodipine on biochemical processes in intact erythrocytes. Bull Exp Biol Med 1991,110(4),1358-1360","journal-title":"Bull Exp Biol Med"},{"key":"ref=141","first-page":"1","volume":"124","author":"Karpova M.N.","year":"1997","unstructured":"Karpova M.N.; Abrosimov I.Y.; Kryzhanovskii G.N.; Effectiveness of combined application of calcium blockers and antiepileptic drugs. Bull Exp Biol Med 1997,124(7),1-4","journal-title":"Bull Exp Biol Med"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/BF02444358","volume":"118","author":"Karpova M.N.","year":"1994","unstructured":"Karpova M.N.; Kryzhanovskii G.N.; Abrosimov I.Y.; Antiseizure and neurotoxic effects of various combinations of phenobarbital, diazepam, sodium valproate and 1, 4-dihydropyridine riodipin. Bull Exp Biol Med 1994,118(7),692-695","journal-title":"Bull Exp Biol Med"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1023\/A:1007816309841","volume":"13","author":"Kim C.S.","year":"1999","unstructured":"Kim C.S.; Matsumori A.; Goldberg L.; Doye A.A.; Mccoy Q.; Gwathmey J.K.; Effects of pranidipine, a calcium channel antagonist, in an avian model of heart failure. Cardiovasc Drugs Ther 1999,13,455-463","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00051131","volume":"10","author":"Rosenthal J.","year":"1996","unstructured":"Rosenthal J.; Hittel N.; Stumpe K.O.; Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: A multicenter, double-blind, placebo-controlled dose-finding study. Cardiovasc Drugs Ther 1996,10(1),59-66","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0014-2999(90)90635-J","volume":"185","author":"Galletti F.","year":"1990","unstructured":"Galletti F.; Luchowski, E. Triggle, D.J. 1,4-Dihydropyridine activators in the tiamdipine series. Eur J Pharmacol 1990,185,157-161","journal-title":"Eur J Pharmacol"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0014-2999(91)90389-8","volume":"195","author":"Galletti I.F.","year":"1991","unstructured":"Galletti I.F.; Zheng W.; Gopalakrishnan M.; Rutledge, Triggle, D.J. Interaction of analogs of the 1,4 dihydropyridine tiamdipine in cardiac and smooth muscle. Eur J Pharmacol 1991,195,125-129","journal-title":"Eur J Pharmacol"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/171854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T09:26:34Z","timestamp":1574241994000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/171854\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":146,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019,9,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557519666190425184749","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}